{
    "title": "Regeneron allays competition fears for 'gold standard' eye drug, shares rise",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11076659/Regeneron-quarterly-profit-slumps-COVID-antibody-sales-dry-up.html",
    "date": "2022-08-03",
    "keywords": [
        "eylea",
        "drug",
        "eye",
        "quarter",
        "competition",
        "regeneron",
        "company",
        "roy",
        "companys",
        "half",
        "category",
        "growth",
        "wednesday",
        "demand",
        "face",
        "year",
        "roche",
        "vabysmo",
        "class",
        "share",
        "status",
        "standard",
        "officer",
        "leonard",
        "schleifer",
        "market",
        "degeneration",
        "population",
        "prevalence",
        "mid",
        "future",
        "executive",
        "marion",
        "day",
        "analyst",
        "bansal",
        "data",
        "catalyst",
        "dosage",
        "term",
        "dupixent",
        "revenue",
        "expectation",
        "fall",
        "decision",
        "use",
        "january",
        "lack",
        "effectiveness",
        "omicron",
        "variant",
        "food",
        "review",
        "application",
        "approval",
        "reporting",
        "bengaluru",
        "editing",
        "shinjini",
        "ganguli"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}